ClinicalTrials.gg

Program

HLX3901

A development code.

In Fosun Pharma's pipeline, DLL3 x CD3 x CD28. Its studies are led by Fosun Pharma.

Furthest: phase 1, since Feb 11, 20261 company-led study, 1 open or runningNext primary completion: May 30, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma11 open or runningphase 1since Feb 11, 2026Feb 11, 2026May 30, 2028phase 1 · NCT07416695
  • Named in Fosun Pharma’s own pipeline as HLX3901 (DLL3 x CD3 x CD28), phase 1, as of Sep 21, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 11, 2026First study: phase 1 study in SCLCFirst studyNCT07416695 · 138 planned · China

Ahead

  1. May 30, 2028Primary completion: phase 1 study in SCLCNCT07416695

TargetBeta

“DLL3 x CD3 x CD28”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07416695SCLC · China1RecruitingMay 30, 2028138

How it is read

Names in the registry

  • “HLX3901”, 1 entry

Codes read as this program: HLX3901.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.